Associate Professor, Department of Pediatrics Emory University School of Medicine Director, Pediatric Neuro-oncology Basic Research Program Children's Healthcare of Atlanta, Egleston
Winship Cancer Institute of Emory University
Dr. Kenney's research focuses on cell cycle control in cerebellar development and medulloblastoma, a pediatric brain tumor that arises in the cerebellum. These tumors are the most common solid malignancy of childhood. Current treatments for medulloblastomas include surgical resection, chemotherapy, and cranio-spinal irradiation. These therapies lead to a 60% "cure" rate, but survivors are left with life long devastating side effects as a result of these treatment, including cognitive declines, seizures, developmental delays, and premature aging. By gaining increased insight into the cellular and molecular mechanisms that drive tumor establishment and growth, it is Dr. Kenney's hope to identify genes and proteins whose activity could in the future be modulated by drugs and novel small molecules, thereby ameliorating the need for irradiation and chemotherapy.
Targeting Medulloblastoma by regulating RNA binding proteins
The Schnepp laboratory focuses on aggressive solid tumors including high-risk neuroblastoma, and rhabdomyosarcoma. Compared to adult tumors, these have few somatic mutations that can be targeted, suggesting the need to identify additional druggable targets. Previous work in the lab has identified
Medulloblastomas comprise the vast majority of pediatric embryonal tumors and by definition arise in the posterior fossa, where they constitute approximately 40% of all posterior fossa tumors. Other forms of embryonal tumors each make up 2% or less of all childhood brain tumors.The clinica